NCT05000450View on ClinicalTrials.gov

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 6, 2021

Primary Completion Date

October 11, 2023

Study Completion Date

October 11, 2023

Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
GENETIC

ALLO-605

ALLO-605 is an anti-BCMA, TRAC/CD52 allogeneic edited, intracellular cytokine signaling containing, CAR T cell product

BIOLOGICAL

ALLO-647

ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen

DRUG

Fludarabine

Chemotherapy for lymphodepletion

DRUG

Cyclophosphamide

Chemotherapy for lymphodepletion

Trial Locations (4)

77030

MD Anderson Cancer Center, Houston

78229

Texas Transplant Institute, San Antonio

78704

St. David's South Austin Medical Center, Austin

80218

Sarah Cannon/Colorado Blood Cancer Institute, Denver

Sponsors
All Listed Sponsors
lead

Allogene Therapeutics

INDUSTRY

NCT05000450 - Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter